Rasburicase
From Wikipedia, the free encyclopedia
 |
|
|
Rasburicase
|
|
| Systematic (IUPAC) name | |
| Aspergillus urate oxidase | |
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C1521H2381N417O461S7 |
| Mol. mass | 34109.5 |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | ? |
| Half life | 8 hrs |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
RX/POM |
| Routes | Intravenous |
Rasburicase (brand names: Fasturtec and Elitek) is a recombinant urate oxidase enzyme that does not occur in human organism. It is used for the prevention and treatment of tumor lysis syndrome in patients receiving chemotherapy for hematologic cancers such as leukemias and lymphomas.
It catalyses the conversion of uric acid to allantoin. Allantoin is much more soluble than uric acid, so renal excretion is more effective.
 |
This enzyme-related article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
